LA JOLLA, Calif., June 1, 2009 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI) today announced plans to double its global production capacity of ultraclean, disposable bioprocess vessels for life sciences applications through upgrades and modifications to its North American manufacturing facility in Bloomington, Minn. The site, which supplies products for the integrated circuit (IC) and flat panel display (FPD) markets, adds a Grade B clean room for fabricating complex three-dimensional storage, mixing and bioreactor vessels for life sciences customers. In addition to maintaining its current IC and FPD operations, the plant upgrade will entail creation of an on-site quality testing laboratory.
"ATMI has been developing and manufacturing one-time use mixing, reactor and storage solutions for the life sciences market for the past few years," said Doug Neugold, ATMI Chief Executive Officer. "As a result of successfully placing multiple qualification units with key North American customers -- and their increasing application of this technology in development and manufacturing -- we're accelerating our investments for production here."
The company will continue its present manufacturing of bioprocess vessels at the ATMI LifeSciences plant in Belgium. By using copy-exact methods from that facility, the company can swiftly replicate a CGMP (Current Good Manufacturing Practices) operation in Minnesota and bring it online -- effectively doubling its global bioprocess vessel capacity. The time-frame targeted for qualifying North American production is 4Q 2009; commercial products are expected to ship in 2010.
"Our customers have asked us to provide them with greater disposable bioprocess vessel capacity, along with global contingency and continuity of supply for their critical ultraclean bioprocess storage, mixing and bioreactor vessels," said Mario Philips, General Manager of ATMI LifeSciences. "Increasing our manufacturing footprint addresses the rapidly increasing demands of the biopharmaceutical marketplace."
Beyond its new Grade B clean room, the upgraded North American facility will house a bio-burden test laboratory to analyze and manage sterility levels in the manufacturing environment. With these additions, ATMI continues to capitalize on its proficiency in semiconductor, clean room and ultrapure manufacturing and to leverage that expertise in the life sciences market.
About ATMI LifeSciences
ATMI LifeSciences is a leader in single-use mixing, storage, and bioreactor technology, fluoropolymer-based products, and custom-engineered, flexible packaging solutions. The business's fundamental knowledge of polymers, specially selected resins, and its clean room manufacturing experience coalesce to help drive optimum performance in critical disposable process operations. For more information, please visit www.atmi-lifesciences.com.
About ATMI
ATMI, Inc. provides specialty semiconductor materials, and high-purity materials handling and delivery solutions designed to increase process efficiencies for the worldwide semiconductor, flat panel, and life sciences industries. For more information, please visit http://www.atmi.com.
ATMI and the ATMI logo are trademarks or registered trademarks of Advanced Technology Materials, Inc., in the United States, other countries or both.
The ATMI, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5254
Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2009 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing and delivering new products; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; and other factors described in ATMI's Form 10-K for the year ended December 31, 2008, and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.